These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

775 related items for PubMed ID: 17671378

  • 21. A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.
    Abbassioun K, Amirjamshidi M, Mehrazin A, Khalatbary I, Keynama M, Bokai H, Abdollahi M.
    Surg Neurol; 2006 Jul; 66(1):26-31; discussion 31. PubMed ID: 16793431
    [Abstract] [Full Text] [Related]

  • 22. Assessment of disease activity in acromegaly by means of a single blood sample: comparison of the 120th minute postglucose value with spontaneous GH secretion and with the IGF system.
    Minuto F, Resmini E, Boschetti M, Arvigo M, Sormani MP, Giusti M, Ferone D, Barreca A.
    Clin Endocrinol (Oxf); 2004 Jul; 61(1):138-44. PubMed ID: 15212656
    [Abstract] [Full Text] [Related]

  • 23. Plasma levels of vascular endothelial growth factor in patients with acromegaly.
    Nagai Y, Ando H, Nohara E, Yamashita H, Takamura T, Kobayashi K.
    Horm Metab Res; 2000 Aug; 32(8):326-9. PubMed ID: 10983629
    [Abstract] [Full Text] [Related]

  • 24. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.
    Minniti G, Jaffrain-Rea ML, Osti M, Esposito V, Santoro A, Solda F, Gargiulo P, Tamburrano G, Enrici RM.
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):210-6. PubMed ID: 15670198
    [Abstract] [Full Text] [Related]

  • 25. Acromegalic features in growth hormone (GH)-deficient patients after long-term GH therapy.
    Carvalho LR, de Faria ME, Osorio MG, Estefan V, Jorge AA, Arnhold IJ, Mendonca BB.
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):788-92. PubMed ID: 14974923
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efficacy of combined octreotide and cabergoline treatment in patients with acromegaly: a retrospective clinical study and review of the literature.
    Suda K, Inoshita N, Iguchi G, Fukuoka H, Takahashi M, Nishizawa H, Yamamoto M, Yamada S, Takahashi Y.
    Endocr J; 2013 Dec; 60(4):507-15. PubMed ID: 23291436
    [Abstract] [Full Text] [Related]

  • 28. The effects of long-term growth hormone and insulin-like growth factor-1 exposure on the development of cardiovascular, cerebrovascular and metabolic co-morbidities in treated patients with acromegaly.
    Jayasena CN, Comninos AN, Clarke H, Donaldson M, Meeran K, Dhillo WS.
    Clin Endocrinol (Oxf); 2011 Aug; 75(2):220-5. PubMed ID: 21521288
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome.
    Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB.
    Clin Endocrinol (Oxf); 2006 May; 64(5):519-22. PubMed ID: 16649970
    [Abstract] [Full Text] [Related]

  • 31. Pioglitazone in acromegaly - an open-label, prospective study.
    Kim DD, Goh J, Panossian Z, Gamble G, Holdaway I, Grey A.
    Clin Endocrinol (Oxf); 2012 Oct; 77(4):575-8. PubMed ID: 22512403
    [Abstract] [Full Text] [Related]

  • 32. Gamma knife radiosurgery for acromegaly--long-term experience.
    Jezková J, Marek J, Hána V, Krsek M, Weiss V, Vladyka V, Lisák R, Vymazal J, Pecen L.
    Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981
    [Abstract] [Full Text] [Related]

  • 33. Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults.
    Krag MB, Rasmussen LM, Hansen TK, Frystyk J, Flyvbjerg A, Møller N, Jørgensen JO.
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):363-8. PubMed ID: 19067726
    [Abstract] [Full Text] [Related]

  • 34. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly.
    Gutt B, Wowra B, Alexandrov R, Uhl E, Schaaf L, Stalla GK, Schopohl J.
    Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):219-24. PubMed ID: 15891958
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Low insulin resistance after surgery predicts poor GH suppression one year after complete resection for acromegaly: a retrospective study.
    Edo N, Morita K, Suzuki H, Takeshita A, Miyakawa M, Fukuhara N, Nishioka H, Yamada S, Takeuchi Y.
    Endocr J; 2016 May 31; 63(5):469-77. PubMed ID: 26949262
    [Abstract] [Full Text] [Related]

  • 38. Are there alternative tests for diagnosis of acromegaly?
    Popovic V.
    J Endocrinol Invest; 2005 May 31; 28(11 Suppl International):73-4. PubMed ID: 16625850
    [Abstract] [Full Text] [Related]

  • 39. Perioperative plasma active and total ghrelin levels are reduced in acromegaly when compared with in nonfunctioning pituitary tumours even after normalization of serum GH.
    Kawamata T, Inui A, Hosoda H, Kangawa K, Hori T.
    Clin Endocrinol (Oxf); 2007 Jul 31; 67(1):140-4. PubMed ID: 17466003
    [Abstract] [Full Text] [Related]

  • 40. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S, Tschopp O, Sze L, Neidert M, Bernays RL, Spanaus KS, Wiesli P, Schmid C.
    Gen Comp Endocrinol; 2013 Jul 01; 188():282-7. PubMed ID: 23648743
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.